Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors

Published on 04 Jun 2025
Last Updated on 04 Jun 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended asciminib for inclusion on the MOH List of Subsidised Drugs for treating Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase in patients previously treated with two or more tyrosine kinase inhibitors. The decision was based on the unfavourable cost-effectiveness of asciminib compared with dasatinib, nilotinib and ponatinib, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for asciminib are provided in the Annex.

Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors (Published 4 Jun 2025)

PES_Asciminib for previously treated Philadelphia chromosome-positive chronic myeloid leukaemia (Published 4 Jun 2025)